Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post Marketing Surveillance Study for MenQuadfi® [Meningococcal (Groups A, C, Y, W) Polysaccharide Tetanus Toxoid Conjugate Vaccine] Administered in Participants Aged 6 Weeks to 55 Years in Republic of Korea

NCT07621653 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT07621653
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07621653 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post Marketing Surveillance Study for MenQuadfi® [Meningococcal (Groups A, C, Y, W) Polysaccharide Tetanus Toxoid Conjugate Vaccine] Administered in Participants Aged 6 Weeks to 55 Years in Republic of Korea
Lead sponsor
Sanofi
Phase
Observational
Overall status
Recruiting
Start date
July 1, 2026
Completion date
November 23, 2027
Enrollment
706 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers, meningococcal immunization